National Human Genome Research Institute

Genomic Analysis Reveals Ancient Cancer Lineages in Clams

Retrieved on: 
星期一, 十月 2, 2023
Columbia University, Clam, Human, University, National Human Genome Research Institute, Nature Cancer, Instability, FISU World University Games, Texas A&M University, Cancer, Mutation, Pacific Northwest Diabetes Research Institute, Assistant, Universidad, University of Maine at Machias, Compostela, University of Washington School of Medicine, Environment, Vaccine, Aquaculture

SEATTLE, Oct. 2, 2023 /PRNewswire-PRWeb/ -- In a new study published in the journal Nature Cancer, Michael Metzger, Ph.D., Assistant Investigator at Pacific Northwest Research Institute (PNRI), and a global team of co-investigators have conducted a comprehensive analysis of the genomic changes associated with a unique cancer in clams. The cancer is "transmissible" in that the cancer cells themselves jump from one clam to another through the environment. The study traced the evolution of the cancer cells over the last 200 years and revealed widespread genomic mutations and instability, which may explain how they have survived for so long. These results highlight the clam's potential as a model for studying both cancer evolution and the development of resilience to cancer.

Key Points: 
  • The cancer is "transmissible" in that the cancer cells themselves jump from one clam to another through the environment.
  • These results highlight the clam's potential as a model for studying both cancer evolution and the development of resilience to cancer.
  • These results highlight the clam's potential as a model for studying both cancer evolution and the development of resilience to cancer.
  • The genomic analysis of cancer in clams advances current knowledge of cancer biology and underscores the importance of studying contagious cancers in their natural settings.

Broken String Biosciences Closes $15M Series A Funding Round

Retrieved on: 
星期一, 九月 18, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, DNA, Platform as a service, Broken String, Investment, Wellcome Genome Campus, NGS, Gene editing, Tencent, Genomics, Doctor of Philosophy, Cas9, Traction, Patient, Polymerase chain reaction, National Human Genome Research Institute, Biology, Growth, Safety, PCR, Genome, Data science, Antibiotics, Vaccine

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures (DvH Ventures).

Key Points: 
  • Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures (DvH Ventures).
  • As part of the round, Yoann Bonnamour, Mérieux Equity Partners, and Arnaud Autret, Illumina Ventures, join the Company’s Board of Directors.
  • Felix Dobbs, PhD, Chief Executive Officer of Broken String Biosciences, commented: “Our vision is a future where cell and gene therapies are safer, more efficient, and affordable for patients.
  • This new funding will enable the technology to be developed and delivered in a format that meets the needs of all customers, ideally positioning the Company for significant growth.”
    To learn more about Broken String Biosciences, please visit brokenstringbio.com

iSpecimen Launches New Virtual Cancer Sequencing Procurement Program

Retrieved on: 
星期三, 八月 30, 2023
NRAS, Tissue, KRAS, National Human Genome Research Institute, TP53, Serum, Breast, Cancer, National Cancer Institute, Brain, Prostate, Lung, Colon, Plasma, The Cancer Genome Atlas, PTEN, EGFR, Risk, Melanoma, DTC, MET, TCGA, RET, ALK, Medical imaging

LEXINGTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the launch of a new program that gives researchers consistent and direct access to mutation-characterized formalin-fixed, paraffin-embedded (“FFPE”) cancer tumor tissues, relieving a major bottleneck in cancer research. The program will initially offer samples for lung, colon and breast cancers.

Key Points: 
  • The genetic signatures of cancer tumor tissues provide important information necessary to develop new treatments and diagnostics.
  • “This is a very important program for the future of iSpecimen.
  • Our new cancer sequencing procurement program provides cancer researchers with access to mutation-characterized FFPE tumor tissues without requiring that they manage the risk and resource-intense course of overseeing the sequencing process,” said Tracy Curley, iSpecimen’s CEO.
  • As this program progresses, pre-screened samples will be offered for a number of additional cancer types, including pancreatic, renal, brain, ovarian, gastric, melanoma, bladder and prostate.

New research from The Jackson Laboratory: Insights from fully sequencing 43 human Y chromosomes

Retrieved on: 
星期五, 八月 25, 2023
Male, DNA, Human, National Human Genome Research Institute, Neoplasm, Y, U24, Genomics, RNA, Disorder, Clemson University, Illar Hallaste, Jackson Laboratory, Chromosome, FACMG, Heinrich Heine University Düsseldorf, Fertility, Euchromatin, JAX, Biology, Paper, Research, Health, Gene, Reference genome, Genome, Disease, Birth control, Antibiotics, Agriculture

Even as the field of human genomics forged ahead at an astonishing pace, the Y chromosome— one of the sex chromosomes—has long remained overlooked.

Key Points: 
  • Even as the field of human genomics forged ahead at an astonishing pace, the Y chromosome— one of the sex chromosomes—has long remained overlooked.
  • Taken together, these two papers provide intriguing insights into human Y chromosomes, reveal the highly variable nature of Y chromosomes across individuals, and provide an important foundation for future studies on how they may be contributing to certain disorders and diseases.
  • "Our study enables the inclusion of the full Y chromosome in all future studies when sequencing male genomes to understand health and disease."
  • The work was supported in part by a U24 grant from the National Human Genome Research Institute (#HG007497).

Henry Schein Congratulates Dr. Louis W. Sullivan for Receiving a 2023 National Humanism in Medicine Medal, Awarded by The Arnold P. Gold Foundation

Retrieved on: 
星期一, 七月 10, 2023
Biotechnology, Medical Supplies, General Health, Health, Medical Devices, Dental, Clinical Trials, Other Health, Outline, National Human Genome Research Institute, Quest Diagnostics, College, Office of Inspector General, U.S. Department of Health and Human Services, Public policy, Henry Schein, Howard University, Human services, Allied health professions, University of Cincinnati Academic Health Center, Health equity, Arnold, Multimedia, Health policy, Morehouse School of Medicine, Nurse education, Corporate Council on Africa, National Tainan Junior College of Nursing, Siemens Healthineers, Association of American Medical Colleges, Gold, Medal, AAHC, Humanism, CVS Health, Ziegfeld Theatre (1969), BD, Management, Nursing, Medallia, Medicine

Henry Schein, Inc. (Nasdaq: HSIC) today celebrates Dr. Louis W. Sullivan for receiving a 2023 National Humanism in Medicine Medal from The Arnold P. Gold Foundation.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC) today celebrates Dr. Louis W. Sullivan for receiving a 2023 National Humanism in Medicine Medal from The Arnold P. Gold Foundation.
  • View the full release here: https://www.businesswire.com/news/home/20230707576139/en/
    Dr. Louis W. Sullivan receives a 2023 National Humanism in Medicine Medal, awarded by The Arnold P. Gold Foundation (Photo: Business Wire)
    Medal recipients were recognized during The Gold Foundation’s Annual Gala held at the Ziegfeld Ballroom in New York City on June 20, 2023.
  • “For more than 16 years, we’ve been privileged to advance health equity and empower health care professionals through our work together at Henry Schein and the Henry Schein Cares Foundation.
  • Henry Schein co-founded The Gold Foundation’s Corporate Council in 2017, and Allison Neale, Henry Schein’s Vice President of Public Policy and Managing Director of the Henry Schein Cares Foundation, serves as the Council’s Chair.

Behind the Scenes of a Major Genomic Discovery: Eimear Kenny plays an integral role in an international scientific effort that produces a more inclusive genome reference

Retrieved on: 
星期三, 五月 10, 2023
Gene conversion, DNA, Genomic Health, Human, Nature, Human genome, National Human Genome Research Institute, Icahn School of Medicine at Mount Sinai, Principal investigator, Mutation, Research, Medicine, Mount Sinai, Genomics, Doctor of Philosophy, Bangladesh Technical Education Board, NHGRI, Genetics, DOI, Chromosome, MD, Collection, James D. Watson Institute of Genome Sciences, Nature Biotechnology, Diagnosis, Health, Bias, Gene, Genome, Antibiotics, Medical device, Vaccine, Agriculture, Science

NEW YORK, May 10, 2023 /PRNewswire-PRWeb/ -- Eimear Kenny, PhD, had just completed undergrad and was working in her first computational genomics job more than 20 years ago when scientists announced the first (nearly) complete sequencing of the human genome—what was considered at the time to be the fundamental blueprint for all humans. The Human Genome Project aimed to map the entire genome in an effort to accelerate the diagnosis and eventual treatment of common and rare diseases.

Key Points: 
  • The Human Genome Project aimed to map the entire genome in an effort to accelerate the diagnosis and eventual treatment of common and rare diseases.
  • The work was led by the international Human Pangenome Reference Consortium, a group funded by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health.
  • "We have had a single human reference for the past 20 years, and this genome reference has been extraordinarily powerful.
  • See press release issued by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health: https://www.genome.gov/news/news-release/scientists-release-a-new-human-...

TScan Therapeutics Announces CEO Transition

Retrieved on: 
星期五, 三月 31, 2023
Scripps Research, University, Senior, Genetics, American Board of Obstetrics and Gynecology, Harvard University, Genomics, Cancer, Research, Southwell, Immunotherapy, Associate, TCR, MacBeath, Harvard Medical School, National Human Genome Research Institute, Discovery, Patient, IND World's Fair Line, Principal, Transplant, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Merrimack Pharmaceuticals, Food, University of Manitoba, Bone marrow, Management, Pharmaceutical industry, Vaccine, Faculty, Chemistry

WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX) (“TScan” or “The Company”), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that its Board of Directors has appointed Gavin MacBeath, Ph.D., as acting Chief Executive Officer (CEO), effective March 28, 2023. He will continue to serve as Chief Scientific and Operating Officer. David Southwell has stepped down as CEO and member of the Board, effective March 27, 2023.

Key Points: 
  • David Southwell has stepped down as CEO and member of the Board, effective March 27, 2023.
  • Dr. MacBeath joined TScan in 2018.
  • Chairman of the Board Timothy Barberich, said, “On behalf of the Board, we look forward to working with Gavin to continue the important work underway at TScan.
  • As of December 31, 2022, TScan Therapeutics had cash and cash equivalents of $120.0 million, excluding $5.0 million of restricted cash.

City of Hope appoints John D. Carpten, Ph.D., as director of its comprehensive cancer center and Beckman Research Institute, and chief scientific officer

Retrieved on: 
星期四, 四月 6, 2023
City of Hope National Medical Center, City of Hope, Cross-Cutting Programs Committee, Genomics, Bangladesh Technical Education Board, Incidence, Patient, Division, Faculty, Translational Genomics Research Institute, Health, Deana, Prostate cancer, University, Genetics, Multiple myeloma, Policy, Keck School of Medicine of USC, National Cancer Institute, Research, Medicine, National Institutes of Health, Biology, Growth, Caligiuri, American Association for Cancer Research, NCI, Distinguishing, Conference, Cell biology, AACR, Cancer, USC, Colorectal cancer, Morgan, Mortality, Workforce, Ohio State University, National Human Genome Research Institute, Education, Irell & Manella Graduate School of Biological Sciences, City, Beckman Research Institute, Breast cancer, Management, Nursing, Hope

LOS ANGELES, April 6, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of John D. Carpten, Ph.D., as director of the National Cancer Institute-designated comprehensive cancer center, director of Beckman Research Institute of City of Hope and chief scientific officer.

Key Points: 
  • LOS ANGELES, April 6, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of John D. Carpten, Ph.D., as director of the National Cancer Institute-designated comprehensive cancer center, director of Beckman Research Institute of City of Hope and chief scientific officer.
  • Carpten will also hold the Irell & Manella Cancer Center Director's Distinguished Chair and the Morgan & Helen Chu Director's Chair of the Beckman Research Institute.
  • "Dr. Carpten's expertise and unwavering commitment to drive and accelerate cancer research and discovery will benefit our patients across the country."
  • As part of this transition, City of Hope's current provost, chief scientific officer, and Beckman Research Institute and cancer center director, Steven T. Rosen, M.D.

American Society of Pharmacovigilance Partners with Invitae Corp. to Co-Host Congressional Reception - 'Powering PGx: Celebrating Advances in a Precision Medicine Approach to Prescription Drugs'

Retrieved on: 
星期四, 三月 23, 2023
ASP, Medical Affairs Bureau, National Human Genome Research Institute, Life, Personalized medicine, Prescription, Government, Congress, Patient, Federation, FDA, Drinking fountain, Lancet, Death, Society, Genome, Pharmaceutical industry, Veteran

Pharmacogenomics is a critical field of study that analyzes how variations in the human genome dictate a person's individual response to medications.

Key Points: 
  • Pharmacogenomics is a critical field of study that analyzes how variations in the human genome dictate a person's individual response to medications.
  • "We lose a life every two minutes in this country to non-optimized medications, the equivalent of four full 737 planes every day," said Kristine Ashcraft, Medical Affairs Director for Invitae.
  • "Adverse drug events are the fourth leading cause of death in the United States," said Rep. Swalwell, co-chair of the Precision Medicine Caucus.
  • Pharmacogenomics testing for Veterans (PHASER) program; Abby Yoder, Patient Advocate; and Rep. Eric Swalwell, Co-Chair of the Personalized Medicine Caucus.

Researchers study enhanced genetic animal model of Down syndrome

Retrieved on: 
星期二, 三月 14, 2023
Learning, Down syndrome, Cognition, National Human Genome Research Institute, Memory, Mouse, Bangladesh Technical Education Board, Human, Behavior, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Biological Psychiatry (journal), National Institutes of Health, Gene, Genetics, NHGRI, Medical device

WASHINGTON, March 14, 2023 /PRNewswire/ -- National Institutes of Health researchers compared a new genetic animal model of Down syndrome to the standard model and found the updated version to be more similar to the changes seen in humans. The new mouse model shows milder cognitive traits compared to a previously studied Down syndrome mouse model. The results of this study, published in Biological Psychiatry, may help researchers develop more precise treatments to improve learning and memory in people with Down syndrome.

Key Points: 
  • WASHINGTON, March 14, 2023 /PRNewswire/ -- National Institutes of Health researchers compared a new genetic animal model of Down syndrome to the standard model and found the updated version to be more similar to the changes seen in humans.
  • The new mouse model shows milder cognitive traits compared to a previously studied Down syndrome mouse model.
  • The results of this study, published in Biological Psychiatry , may help researchers develop more precise treatments to improve learning and memory in people with Down syndrome.
  • Scientists often use different strains of mice as animal models to study human diseases because most genes in humans have similar counterparts in mice.